MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
NovaBay Pharmaceuticals Cash Conversion Cycle 2011-2026 | NBY
Annual Cash Conversion Cycle NovaBay Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -14.5 | 116 | 150 | 123 | 68.8 | 92.8 | 36.1 | 79.4 | 132 | -285 | -915 | -3.17 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 150 | -3.17 K | -299 |
Quarterly Cash Conversion Cycle NovaBay Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -64.8 | - | - | - | -1.26 | -31.5 | -18.9 | - | 263 | 123 | 309 | - | 184 | 119 | 127 | - | 5.71 | 36.5 | 32.4 | - | 52.1 | 13.7 | 36.7 | - | 36.6 | 36.5 | -14.7 | - | -74.5 | -51.6 | -42.4 | - | 6.65 | 4.97 | 35.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 309 | -74.5 | 44.9 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adagene
ADAG
|
53.8 | $ 2.62 | 28.82 % | $ 147 M |  China |
 |
GlaxoSmithKline plc
GSK
|
0.02 | $ 48.98 | 0.68 % | $ 173 B |  Britain |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K |  USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-8.96 K | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 9.25 | 1.49 % | $ 6.83 B |  Spain |
 |
Amphastar Pharmaceuticals
AMPH
|
166 | $ 25.92 | -0.86 % | $ 1.26 B | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Galapagos NV
GLPG
|
67.1 | $ 34.61 | 0.61 % | $ 2.69 B |  Belgium |
 |
Ultragenyx Pharmaceutical
RARE
|
63.6 | $ 24.45 | 4.49 % | $ 2.21 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
BioXcel Therapeutics
BTAI
|
-2.28 K | $ 1.84 | 1.66 % | $ 4.66 M | USA |
 |
Aytu BioScience
AYTU
|
174 | $ 2.66 | -1.85 % | $ 16.7 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 67.49 | -3.02 % | $ 9.03 B | USA |
 |
Brickell Biotech
BBI
|
149 | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | Britain |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Coherus BioSciences
CHRS
|
326 | $ 2.04 | 28.3 % | $ 192 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Biogen
BIIB
|
387 | $ 171.89 | -1.1 % | $ 25 B | USA |